Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trial Long-term safety data from a 52-week open-label extension trial in this age group reinforce the well-established safety profile of Dupixent observed across all other approved age groups Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy through adulthood TARRYTOWN, N.Y. and PARIS , June 7, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

GlaxoSmithKline

Pfizer

Could these biotech stocks be worth keeping an eye on in the stock market today?

What Stocks To Buy Today? 3 Biotech Stocks To Know

Jefferies initiates coverage of Regeneron Pharmaceuticals at Underperform, sending the stock lower.

Regeneron Gets Wall Street-Low Price Target. The Stock May Be Done Outperforming the Market.

Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.

Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Regeneron (REGN) Down 1.4% Since Last Earnings Report: Can It Rebound?

The company is forking over $900 million in an upfront payment to fully own a cancer drug.

Why Regeneron Wasn't a Healthy Stock Today

Sanofi

Regeneron will gain exclusive worldwide development, commercialization, and manufacturing rights to the drug Libtayo.

Regeneron Will Buy Cancer Drug Rights From Sanofi for Up to $1.1 Billion

Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collaboration on cancer treatment Libtayo.

Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration

Regeneron will secure global rights to Libtayo from Sanofi in exchange for upfront payment of $900 million, plus royalties and potential future milestone payments 18 different investigational treatment combinations with Libtayo currently being evaluated in 22 clinical trials Regeneron will host an investor conference call today at 8:30 am ET; dial-in details are available below TARRYTOWN, N.Y. , June 2, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its intent to purchase Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine.

Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer

Checkmate Pharmaceuticals

XOMA

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules

Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) for the lead drug candidate Dupixent (dupilumab) for the treatment of patients with prurigo.

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

Acquisition strengthens Regeneron's innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment TARRYTOWN, N.Y. , May 31, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology and adding a new modality to the company's portfolio of potential combination-ready approaches for difficult-to-treat cancers.

Regeneron Completes Acquisition of Checkmate Pharmaceuticals

FDA accepts Dupixent ® (dupilumab) for priority review in adult s with prurigo nodularis

Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis

TARRYTOWN, N.Y. and PARIS , May 31, 2022 /PRNewswire/ -- Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® Medical (dupilumab) to treat adults with prurigo nodularis, a chronic skin disease that causes extreme itch and inflammatory skin lesions (nodules).

FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

New treatments will step in to replace blockbuster eye medication EYLEA.

Why Regeneron Investors Shouldn't Fear Its Patent Cliff

Alkermes

Sesen Bio Inc.

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.

Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

Regeneron has a very strong pipeline consisting of treatments that can complement current cash cows (EYLEA and Dupixent) along with potential blockbusters. Even if EYLEA rapidly loses market share after its patent expirations, the growth from Dupixent and Libtayo will be more than enough to offset the loss.

Regeneron: Bright Future Ahead

TARRYTOWN, N.Y. , May 21, 2022 /PRNewswire/ -- Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C reduced by at least half at 24 weeks FDA submission planned by end of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial evaluating Evkeeza® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH).

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol

Regeneron just posted another impressive quarter for earnings (+16% YoY) and revenues (+17% YoY). Growth is set to slow after a one-time boost from its COVID antibody cocktail last year and an upcoming patent expiry for Eylea.

Regeneron's Growth Set To Slow, But Could Outperform Downbeat Consensus Forecasts

FDA a pproves Dupixent ® (dupilumab) as f irst t reatment for adult s and children aged 12 and older with e osinophilic e sophagitis

Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

TARRYTOWN, N.Y. and PARIS , May 20, 2022 /PRNewswire/ -- Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly significantly improved signs and symptoms of eosinophilic esophagitis compared to placebo in a Phase 3 trial, underscoring the role of type 2 inflammation in this complex disease Eosinophilic esophagitis is a chronic, progressive inflammatory disease driven by type 2 inflammation that damages the esophagus and prevents it from working properly Approval represents first indication for Dupixent in a gastrointestinal disease and fourth disease indicated overall Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.

FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM: CMPI) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Checkmate will receive only $10.50 in cash for each share of Checkmate that they own. KSF is seeking to determine whether this consideration and the

CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

ROCHESTER, Minn. , May 17, 2022 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr.

News for Regeneron Pharmaceuticals Stock (REGN)